Stay updated on Duvelisib in Refractory Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Duvelisib in Refractory Lymphoma Clinical Trial page.

Latest updates to the Duvelisib in Refractory Lymphoma Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedRevision: v3.4.2 is now displayed, replacing the previous v3.4.1. No study data or key page content appear to be affected.SummaryDifference0.0%

- Check19 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1 and no user-facing content or study details were changed; to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check33 days agoChange DetectedShow glossary and Hide glossary options were added to control glossary visibility. Capitalization adjustments were made for 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data', and a new 'Revision: v3.4.0' stamp was introduced.SummaryDifference0.2%

- Check41 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4; no substantive changes to the Study Details page were observed in the screenshots. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check69 days agoChange DetectedUpdated the study locations section to include detailed site locations by state/province and country (including Minsk Oblast, Ontario, and Quebec) and updated the revision to v3.3.3.SummaryDifference2%

- Check90 days agoChange DetectedA note was added clarifying that PubMed publications are automatically populated and may not all relate to the study, and the revision label was updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

Stay in the know with updates to Duvelisib in Refractory Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Duvelisib in Refractory Lymphoma Clinical Trial page.